Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
KMDA | US
-0.03
-0.57%
Healthcare
Biotechnology
30/06/2024
04/10/2024
5.20
5.24
5.24
5.17
Kamada Ltd. together with its subsidiaries provides plasma-derived protein therapeutics. It operates in two segments Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot Israel.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Negative Momentum (Declining Price)
Price Below SMA10D
Microcap (<300M USD)
Weak P/E, and PEG ratio indicator
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
18.8%1 month
25.6%3 months
40.6%6 months
37.2%20.04
20.53
1.24
0.03
0.02
8.44
1.57
8.75
28.43M
298.89M
298.89M
-
13.28
100.00
13.40
7.05
0.46
0.06
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.30
Range1M
0.42
Range3M
1.36
Rel. volume
0.51
Price X volume
69.64K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
XOMA Corporation | XOMA | Biotechnology | 27.64 | 323.51M | 0.95% | n/a | 121.93% |
MeiraGTx Holdings plc | MGTX | Biotechnology | 4.15 | 320.31M | -1.89% | n/a | 109.40% |
ADC Therapeutics SA | ADCT | Biotechnology | 3.29 | 318.10M | 8.22% | n/a | -94.48% |
Aldeyra Therapeutics Inc | ALDX | Biotechnology | 5.34 | 317.31M | 0.75% | n/a | 15.90% |
Cerus Corporation | CERS | Biotechnology | 1.7 | 315.00M | 0.59% | n/a | 199.34% |
Immutep Limited | IMMP | Biotechnology | 2.05 | 314.34M | -3.07% | n/a | 0.84% |
Monte Rosa Therapeutics Inc | GLUE | Biotechnology | 5.09 | 312.39M | -5.57% | n/a | 19.74% |
Lyell Immunopharma Inc. Common Stock | LYEL | Biotechnology | 1.22 | 312.32M | -0.81% | n/a | 10.63% |
PEPG | PEPG | Biotechnology | 9.3 | 303.08M | 2.88% | n/a | 12.52% |
STROUDS INC | STRO | Biotechnology | 3.61 | 295.89M | 2.85% | n/a | 125.14% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.89 | 19.79M | -2.50% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 8.44 | 0.76 | Expensive |
Ent. to Revenue | 1.57 | 3,674.48 | Cheaper |
PE Ratio | 20.04 | 38.01 | Cheaper |
Price to Book | 1.24 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 40.59 | 74.67 | Lower Risk |
Debt to Equity | 0.03 | -1.82 | Expensive |
Debt to Assets | 0.02 | 0.26 | Cheaper |
Market Cap | 298.89M | 3.73B | Emerging |